Evidence map›Paper›PMID 33584158›Full record

ArticleApplied soft computing2021

Forecasting the dynamics of cumulative COVID-19 cases (confirmed, recovered and deaths) for top-16 countries using statistical machine learning models: Auto-Regressive Integrated Moving Average (ARIMA) and Seasonal Auto-Regressive Integrated Moving Average (SARIMA).

K E ArunKumar, Dinesh V Kalaga, Ch Mohan Sai Kumar, Govinda Chilkoor, Masahiro Kawaji, Timothy M Brenza

Abstract read
In one paragraph

Article in Applied soft computing, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

K E ArunKumarDepartment of Chemical and Biological Engineering, South Dakota School of Mines and Technology, Rapid City, SD 57701, USA.
Dinesh V KalagaMechanical Engineering Department, City College of New York, New York, NY 10031, USA.
Ch Mohan Sai KumarProcess Chemistry and Technology, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, UP, 226015, India.
Govinda ChilkoorDepartment of Civil and Environmental Engineering, South Dakota School of Mines and Technology, Rapid City, SD, 57701, USA.
Masahiro KawajiMechanical Engineering Department, City College of New York, New York, NY 10031, USA.
Timothy M BrenzaDepartment of Chemical and Biological Engineering, South Dakota School of Mines and Technology, Rapid City, SD 57701, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most countries are reopening or considering lifting the stringent prevention policies such as lockdowns, consequently, daily coronavirus disease (COVID-19) cases (confirmed, recovered and deaths) are increasing significantly. As of July 25th, there are 16.5 million global cumulative confirmed cases, 9.4 million cumulative recovered cases and 0.65 million deaths. There is a tremendous necessity of supervising and estimating future COVID-19 cases to control the spread and help countries prepare their healthcare systems. In this study, time-series models - Auto-Regressive Integrated Moving Average (ARIMA) and Seasonal Auto-Regressive Integrated Moving Average (SARIMA) are used to forecast the epidemiological trends of the COVID-19 pandemic for top-16 countries where 70%-80% of global cumulative cases are located. Initial combinations of the model parameters were selected using the auto-ARIMA model followed by finding the optimized model parameters based on the best fit between the predictions and test data. Analytical tools Auto-Correlation function (ACF), Partial Auto-Correlation Function (PACF), Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) were used to assess the reliability of the models. Evaluation metrics Mean Absolute Error (MAE), Mean Square Error (MSE), Root Mean Square Error (RMSE) and Mean Absolute Percent Error (MAPE) were used as criteria for selecting the best model. A case study was presented where the statistical methodology was discussed in detail for model selection and the procedure for forecasting the COVID-19 cases of the USA. Best model parameters of ARIMA and SARIMA for each country are selected manually and the optimized parameters are then used to forecast the COVID-19 cases. Forecasted trends for confirmed and recovered cases showed an exponential rise for countries such as the United States, Brazil, South Africa, Colombia, Bangladesh, India, Mexico and Pakistan. Similarly, trends for cumulative deaths showed an exponential rise for countries Brazil, South Africa, Chile, Colombia, Bangladesh, India, Mexico, Iran, Peru, and Russia. SARIMA model predictions are more realistic than that of the ARIMA model predictions confirming the existence of seasonality in COVID-19 data. The results of this study not only shed light on the future trends of the COVID-19 outbreak in top-16 countries but also guide these countries to prepare their health care policies for the ongoing pandemic. The data used in this work is obtained from publicly available John Hopkins University's COVID-19 database.

Indexed as

Akaike Information Criteria (AIC)ARIMAAuto-Correlation Function (ACF)Bayesian Information Criterion (BIC)COVID-19PandemicSARIMAStatistical modelingTime-series forecast

Identifiers

PMID33584158
PMCPMC7869631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.